NEW GENERATION BTK INHIBITORS AND RESISTANCE IN CLL TREATMENT
Chronic lymphocytic leukemia (CLL) is an indolent lymphoproliferative malignancy characterized by monoclonal B lymphocytosis. BCR signaling plays a critical role in B cell development and survival.Bruton Tyrosine Kinase inhibitors (BTKi) disrupt the BCR signaling pathway by inactivation of BTK, lead...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029389 |